MEDICINOVA INC
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
MNOV$1.40-4.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Years ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenues | $409,657 | $— |
| Operating expenses: | ||
| Cost of services | 378,606 | — |
| Research, development and patents | 7,154,848 | 7,194,731 |
| General and administrative | 6,159,205 | 5,480,600 |
| Total operating expenses | 13,692,659 | 12,675,331 |
| Operating loss | (13,283,002) | (12,675,331) |
| Interest income | 1,303,792 | 1,670,804 |
| Other expense, net | (12,753) | (39,485) |
| Loss before income taxes | (11,991,963) | (11,044,012) |
| Income tax expense | (5,994) | (5,537) |
| Net loss | $(11,997,957) | $(11,049,549) |
| Basic and diluted net loss per common share | $(0.24) | $(0.23) |
| Shares used to compute basic and diluted net loss per common share | 49,063,438 | 49,046,246 |
| Net loss | $(11,997,957) | $(11,049,549) |
| Other comprehensive income (loss), net of tax: | ||
| Foreign currency translation adjustments | 7,974 | (17,064) |
| Comprehensive loss | $(11,989,983) | $(11,066,613) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.